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In endothelial cells, endo-exocytic traffic of active α5β1 integrins and polarized fibronectin 
secretion allow vascular morphogenesis. A new study unveils how the endothelial small GTPase 
RHOJ, by repressing active α5β1 integrin traffic, controls fibronectin polymerization and in vivo 
angiogenesis. 
 
In vertebrates, the formation of functional blood vessel trees ensures the effective delivery of oxygen and 
nutrients to tissues and organs along with the removal of waste products. In the developing embryo, 
endothelial cell (EC) progenitors first self-assemble by vasculogenesis into primitive vessels, which are 
then reshaped by sprouting angiogenesis (and fusion) into hierarchically-organized and arborized 
vascular networks, finally enabling the optimal circulation of blood throughout the body [1]. Similarly, 
cancer growth also relies on newly formed angiogenic vasculature. However, blood vessels of most solid 
tumors display abnormal structure and function, suboptimal perfusion, and hypoxia that instigates 
metastatic dissemination [2]. 
Dynamic adhesive cell interactions to surrounding extracellular matrix (ECM) protein polymers 
are crucial for assembly, remodeling, and stabilization of endothelial tubes [3]. Among ECM 
components, fibronectin (FN) supports blood vessel formation and angiogenic rehandling, while 
laminins impair vascular morphogenesis and maintain the stability of mature arteries, capillaries, and 
veins [3].  EC adhesion to the ECM is mediated by integrins, which are a family 24 heterodimeric 
transmembrane receptors, each arising from the combination of different α and β subunits [4]. Both FN 
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and its major endothelial receptor α5β1 integrin, in cooperation with αvβ3 integrin, are fundamental for 
physiological vascular morphogenesis in vivo [5]. 
Integrins can display either a bent/closed (inactive) or an extended/open (active) conformation that 
respectively binds ECM ligands with low and high affinity [6]. On the cell surface, inactive integrins are 
homogeneously distributed, whereas active integrins are highly enriched in ECM adhesion sites. As a 
rule, morphogenetic events rely on the modulation of cell adhesion to the ECM in space and time. This 
fine control depends not only on the regulation of integrin allosteric conformation [6], but also endosomal 
traffic to and from the plasma membrane of both inactive and active integrin conformers via a complex, 
and only partially characterized, network of functionally distinct pools of cytosolic vesicles [4, 7]. In this 
issue of Current Biology Sundararaman et al. [8] unveil how the endothelial small GTPase RHOJ, which 
is known to control vascular morphogenesis [9, 10], acts by selectively regulating the traffic of active, 
but not inactive α5β1 integrin, thus finely tuning the assembly of FN into polymeric fibrils both in 
cultured ECs and in vivo, thus allowing physiological angiogenesis to occur (Summarized in Figure 1). 
The turnover of fibrillar FN networks is key to both physiologic and pathologic angiogenesis. In 
ECs, upon matrix metalloprotease-dependent cleavage of FN fibrils, FN fragment-bound active α5β1 
integrins are internalized in a RAB21-dependent manner in early endosomes and trafficked to post-Golgi 
carrier (PGC) vesicles that bud from the trans-Golgi network (TGN) and contain freshly synthesized FN 
[11]. Once in PGCs, labelled by TGN protein 46 kD (TGN46), active α5β1 integrins detach from FN 
fragments and, together with new FN dimers, are trafficked along a RAB11B-dependent route to the 
basolateral side of the endothelial plasma membrane [11]. Here, PGCs exocytose freshly synthesized FN 
and recycled active α5β1 integrins close to existing fibrillar adhesions under the control of the protein 
tyrosine phosphatase receptor type f polypeptide (PTPRF)/PTPRF interacting protein a1 (PPFIA1, aka 
liprin-α1) complex [11] (Figure 1). Recent proteomic studies established that, in addition to FN, 
PPFIA1/liprin-α1 also drives the basolateral secretion of the basement membrane organizing protein 
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dystroglycan-1 [12]. Therefore, the PPFIA1/liprin-α1 adaptor may control the polarized exocytosis of 
ECM proteins  in ECs of both angiogenic and quiescent blood vessels [3]. In this context, a major issue 
is represented by the identification of the molecular mechanisms in charge of directing internalized active 
α5β1 integrins towards a recycling or degradative fate in PGCs or late endosomes/lysosomes, 
respectively. 
Prototypical RHO small GTPases, such as RHOA, RAC1 and CDC42 are well-known for their 
crucial function in the control of actin polymerization, cell shape and cell motility. However, archetypal 
RHO GTPases along with new family members, appeared during vertebrate evolution (e.g. RHOC and 
RHOG), their downstream effectors, and the actin cytoskeleton have also been involved in several steps 
of transmembrane receptor traffic [13], ranging from internalization to endosomal sorting towards either 
plasma membrane or TGN [4, 13]. Furthermore, CDC42 was recently shown to regulate bidirectional 
transport within the Golgi apparatus [14] and anterograde transport from the TGN to the plasma 
membrane [15]. 
Sundararaman et al. [8] provide novel evidence about the role that the CDC42-related RHO family 
member RHOJ plays in controlling active α5β1 integrins internalization and post-endocytic traffic in 
ECs, where this small GTPase localizes in early endosomes (EEs), late endosomes/lysosomes (LEs/LYs), 
but not PGCs. α5β1 integrin is the main cargo of RHOJ containing vesicles. In ECs, the lack of RHOJ 
increases, while the overexpression of constitutively active RHOJ decreases, the amount of active α5β1 
integrin that localizes in elongated fibrillar adhesions. The Authors also reveal how, in cultured ECs, 
RHOJ silencing favors the sorting of endocytosed active, but not inactive α5β1 integrins towards PGCs, 
while reducing their accumulation in the LE/LY compartment. Intriguingly, the absence of RHOJ also 
increases the quantity of active, but not inactive α5β1 integrins that progressively accumulates in 
endosomes, particularly at later time points after internalization. On the contrary and differently from 
PTPRF and PPFIA1 [7, 11], RHOJ does not exert any effect on the recycling to the cell surface of 
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endocytosed active or inactive α5β1 integrin. These data may suggest that in ECs RHOJ inhibits active 
α5β1 integrin internalization from fibrillar adhesions. However, the significantly higher late 
accumulation of endocytosed active α5β1 integrins in PGCs rather than LEs/LYs in ECs devoid of RHOJ 
may instead imply that RHOJ may principally act by promoting lysosomal degradation of a sizeable 
fraction of active α5β1 integrins. Further investigations are required to clarify this aspect. 
In agreement with their conclusions on active α5β1 integrins, Sundararaman et al. [8] show that 
RHOJ silencing enhances the ability of ECs to polymerize both endogenous and exogenous soluble FN 
into an insoluble matrix, while active RHOJ overexpression results in the opposite effect. Since 
endogenous FN secretion is not affected by either the lack or the constitutive activation of RHOJ, it is 
conceivable that the effect of RHOJ on FN polymerization in ECs is not direct, rather deriving from the 
regulation of active α5β1 integrin levels. Of note, the Authors also report that, when compared to RHOJ, 
silencing its close relative CDC42 or overexpressing a constitutively active isoform of it result in fully 
complementary effects on FN polymerization, suggesting that CDC42 and RHOJ are two closely related 
small GTPases that may reciprocally inhibit each other to control active α5β1 integrin levels and FN 
fibrillogenesis. Sundararaman et al. [8] identify p21 (RAC1) activated kinase 3 (PAK3) as a shared 
effector protein for whose binding CDC42 may compete with RHOJ. PAK3 interacts with higher affinity 
with CDC42 than with RHOJ. Indeed, similarly to CDC42, silencing or overexpression of PAK3 in ECs 
respectively impairs or increases the polymerization of endogenous FN without affecting its secretion. 
Furthermore, activated RHOJ suppresses the promotion of FN fibrillogenesis elicited by PAK3 
overexpression. However, ECs lacking PAK3 do not display alterations of active α5β1 integrin 
endocytosis. Therefore, shared effector proteins other than PAK3 are likely involved in the antagonistic 
control of active α5β1 integrin traffic and FN fibrillogenesis by RHOJ and CDC42 in ECs. In this regard, 
in addition to PAK1 [8], formin-like protein 3 (FMNL3), which mediates the CDC42-driven anterograde 
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traffic from TGN to plasma membrane [15] and participates in the control of RHOJ on EC polarity [16], 
is an attractive candidate. 
Finally, Sundararaman et al. [8] also reveal how FN deposition markedly increases around retinal 
blood vessels of RHOJ knock-out mice, which are significantly delayed in radial growth and 
characterized by a marked increase of empty ECM sleeves [9]. Altogether, these data bolster the in vivo 
relevance of the RHOJ-dependent control of active α5β1 integrin traffic and FN fibrillogenesis in ECs. 
During physiological blood vessel formation, the action of angiogenic stimulators, such as vascular 
endothelial growth factor (VEGF), is balanced by angiogenic inhibitors, such as semaphorins [2]. This 
equilibrium is lost in pathological cancer angiogenesis [2], e.g. due to hypersecretion of VEGF or lack 
of semaphorins [17, 18]. The notion that VEGF [19] and semaphorins [20] oppositely modulate CDC42 
and RHOJ activation in ECs further emphasizes the implications of  the study of Sundararaman et al. [8]. 
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Figures 
Figure 1. Reciprocal inhibition of closely-related small GTPases RHOJ and CDC42 controls active 
α5β1 integrin traffic and FN fibrillogenesis. During angiogenesis, the formation and proper 
morphogenesis of newly formed blood vessels crucially depend on the dynamic regulation of active α5β1 
integrin traffic along with FN secretion, polymerization, and turnover [7, 11]. RHOJ negatively regulates 
the accumulation of internalization FN-fragment-bound active α5β1 integrins in early endosomes (EEs) 
and their traffic towards post-Golgi carrier vesicles (PGCs), while promoting their targeting to 
degradative late endosomes/lysosomes (LEs/LYs) [8]. The accumulation of internalized active α5β1 
integrins upon RHOJ silencing in ECs may be due to the loss of RHOJ-driven inhibition of endocytosis 
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from the plasma membrane and/or stimulation of degradation in LEs/LYs. The lack of RHOJ favors 
active α5β1 integrin localization in PGCs [8]. Hence, RHOJ may act at the trafficking junction where 
internalized active α5β1 integrins are directed either to PGCs, from which they recycle, or to LEs/LYs, 
where they can be degraded; RHOJ may inhibit the former and promote the latter pathway. CDC42, 
which, via FMNL3, promotes the PGC-mediated anterograde traffic of secretory cargoes from the TGN 
to the plasma membrane [15], counteracting RHOJ inhibition of FN polymerization [8]. The mutual 
inhibition between CDC42 and RHOJ may depend on their competition for the binding to shared effector 
proteins, such as PAK3 and PAK1. Since PAK3 impacts on FN polymerization, but not active α5β1 
integrin traffic [8], other CDC42 and RHOJ shared effectors, e.g. FMNL3, may be likely involved. RHOJ 
interaction and signaling via FMNL3 [16] is not depicted. In ECs, active α5β1 integrin recycling and 
basolateral FN secretion depend on transmembrane PTPRF receptor and PPFIA1 adaptor protein that 
localize in proximity of fibrillar adhesions [7, 11]. Endocytosed inactive α5β1 integrins are immediately 
recycled back to the cell surface from a RAB4-containing early endosomal compartment [11]. 
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